Jun Gui, Farima Zahedi, Angelica Ortiz, Christina Cho, Kanstantsin V. Katlinski, Kevin Alicea-Torres, et al. Nature Cancer.
Sima Patel, Shuyu Fu, Jerome Mastio, George A. Dominguez, Abhilasha Purohit, Andrew Kossenkov, Cindy Lin, Kevin Alicea-Torres, et al. Nature Immunology.
Sushil Kumar, David W. Wilkes, Nina Samuel, Mario Andres Blanco,Anupma Nayak, Kevin Alicea-Torres, et al. Journal of Clinical Investigation.
Filippo Veglia, Vladimir A. Tyurin, Dariush Mohammadyani, Maria Blasi, Elizabeth K. Duperret, Laxminarasimha Donthireddy, Ayumi Hashimoto, Alexandr Kapralov, Andrew Amoscato, Roberto Angelini, Sima Patel, Kevin Alicea-Torres, et al. Nature Communications.
Thomas Condamine, George A. Dominguez, Je-In Youn, Andrew V. Kossenkov, Sridevi Mony, Kevin Alicea-Torres, et al. Science Immunology.
English and Spanish
Kevin Alicea-Torres & Dmitry I. Gabrilovich. Oncoimmunology. Springer, Cham.
The accumulation of highly immunosuppressive myeloid cells known as myeloid-derived suppressor cells (MDSCs) is one of the immunological hallmarks of cancer. MDSCs are a heterogeneous population of bone marrow-derived immature myeloid cells that accumulate in the blood, peripheral lymphoid organs, and tumor tissues, which correlates with a poor clinical outcome in cancer patients. The main feature of MDSCs is their ability to suppress antitumor responses leading to tumor progression. Thus, MDSCs represent an attractive therapeutic target to enhance antitumor responses in cancer.